January is a time when many smokers strengthen their resolve to kick their habit, with 1.2 million estimated to have embarked on this journey this New Year’s Day in the UK alone. However, as smokers who have attempted and failed to quit will agree, will power by itself is often insufficient and smoking cessation aids are often needed. Estimated to be worth just $213 million in 2006, a new report finds that the prescription nicotine dependence market is set to grow strongly at a compound annual growth rate (CAGR) of 16% to reach $4.6 billion by 2016, driven by the launch of two promising pipeline nicotine vaccines and the continued uptake of Pfizer’s popular nicotine receptor agonist Chantix (varenicline).

Continue reading “Anti-Smoking Vaccines Helping to Kick the Habit & Ignite Underdeveloped Prescription Market” »